Components of the tumour‐promoting inflammation and the avoiding immune destruction hallmarks were enriched in several modules and were detected in all data sets (Tables S1, S4, S7).Because only a minority of patients within a given cancer type respond to CD8+T cell dependent cancer immunotherapy,35induction of CD8+T cell recruitment and activation 36or inclusion of innate immune processes such as NK‐cell activation are being developed.37 This expansion requires characterization of biomarkers defining an antitumoral immune response. This evidence concerns the gene CD8A and cancer.